{"entity":{"id":"allotera-therapeutics","kind":"company","name":"Allotera Therapeutics (formerly Wugen)","aka":[],"tldr":"Allotera, formerly Wugen, makes off-the-shelf CAR T-cell therapies from healthy donor cells for T-cell leukaemias and lymphomas, which are hard to treat with conventional CAR T because the cancer cells look like the therapy cells. Its lead product is in a global pivotal trial.","summary":"Allotera Therapeutics (renamed from Wugen in July 2026) is a St. Louis clinical-stage company developing allogeneic, off-the-shelf cell therapies for haematological malignancies. Lead candidate soficabtagene geleucel (sofi-cel, formerly WU-CART-007) is an anti-CD7 allogeneic CAR T-cell therapy in the global pivotal T-RRex trial for relapsed or refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma, with further work in T-cell non-Hodgkin lymphoma, acute myeloid leukaemia and autoimmune indications. The programme was selected for the FDA's CMC Development and Readiness Pilot. In July 2026 the company closed a $35 million financing of equity and venture debt, bringing its Series C to $150 million and total capital raised to $150 million on top of the $115 million Series C announced in late 2025, to fund T-RRex, manufacturing scale-up and team growth.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://alloteratx.com/"},{"label":"$35 million financing and rename (July 2026)","url":"https://alloteratx.com/allotera-therapeutics-formerly-wugen-closes-35-million-financing-to-advance-off-the-shelf-car-t-therapies-for-t-cell-cancers/"}],"tags":[],"related":[],"cancers":["all-leukemia","aml"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06514794"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["wugen.com redirects to alloteratx.com. Investor names not given in the fetched release. Earlier Wugen rounds (for example the 2021 Series B) not sourced."],"hq":"St. Louis, MO","country":"US","companyType":"cell-therapy","website":"https://alloteratx.com/","stage":"growth","investors":[],"funding":[{"round":"Series C","year":2025,"amountUsd":115000000,"source":"https://alloteratx.com/allotera-therapeutics-formerly-wugen-closes-35-million-financing-to-advance-off-the-shelf-car-t-therapies-for-t-cell-cancers/","note":"Series C announced in late 2025 as stated in the July 2026 release"},{"round":"Series C","year":2026,"amountUsd":35000000,"source":"https://alloteratx.com/allotera-therapeutics-formerly-wugen-closes-35-million-financing-to-advance-off-the-shelf-car-t-therapies-for-t-cell-cancers/","note":"Additional equity and venture debt closed 8 July 2026, bringing the Series C total to $150 million"}]},"route":"/companies/allotera-therapeutics/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"trial":[{"id":"nct06514794","kind":"trial","name":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","route":"/trials/nct06514794/"}]}}